Oxyntomodulin Heavy

HSQGTFTSDYSKY-[U-13C6,15N-Leu]-DSRRAQD-[U-13C9,15N-Phe]-VQW-[U-13C6,15N-Leu]-MNTKRNRNNIA-acid

  • Description

  • Application Data

Description

Oxyntomodulin is a glucose- and appetite-regulating gut hormone. Contains two leucine residues and a phenylalanine residue labelled with stable 13C and 15N isotopes.

See full description

Application Data

Catalogue number crb1300756
Molecular Weight 4471.2
Sequence (one letter code)

HSQGTFTSDYSKY-[U-13C6,15N-Leu]-DSRRAQD-[U-13C9,15N-Phe]-VQW-[U-13C6,15N-Leu]-MNTKRNRNNIA-acid

Sequence (three letter code)

H-His-Ser-Gln-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Lys-Tyr-[U-13C6,15N-Leu]-Asp-Ser-Arg-Arg-Ala-Gln-Asp-[U-13C9,15N-Phe]-Val-Gln-Trp-[U-13C6,15N-Leu]-Met-Asn-Thr-Lys-Arg-Asn-Arg-Asn-Asn-Ile-Ala-OH

Purity >95%
Storage -20°C
References

Albrechtsen et al., (2016). Oxyntomodulin Identified as a Marker of Type 2 Diabetes and Gastric Bypass Surgery by Mass-spectrometry Based Profiling of Human Plasma. EBioMedicine. 7: 112. PMID: 27322465

 

Price et al., (2015). Increased food intake with oxyntomodulin analogues. Peptides73: 95. PMID: 26431789

Manufactured in: United Kingdom
Data Sheet Material Safety Data Sheet (MSDS)

Oxyntomodulin is a glucose- and appetite-regulating gut hormone which may work with GLP-1 in the regulation of glucose metabolism and appetite in humans. Secretion of oxyntomodulin is significantly impaired in patients with type 2 diabetes, suggesting it may contribute to the pleiotropic pathophysiology of the disease.

Oxyntomodulin is the 29 amino acids of glucagon with an additional C-terminal octapeptide tail. It is produced from proglucagon precursor peptide, along with glucagon-like peptide-1 (GLP-1), glucagon and glucagon-like peptide-2 (GLP-2). Oxyntomodulin activates both the human glucagon receptor and GLP-1 receptor, albeit with reduced efficacy compared to the native peptides. Oxyntomodulin reduces food intake via activity at the GLP-1 receptor, while its activity at the glucagon receptor causes weight loss by increasing energy expenditure.

Oxyntomodulin levels are increased by more than 10-fold after gastric bypass surgery, therefore oxyntomodulin analogues many offer novel treatments for obesity. Chronic oxyntomodulin administration improves glucose tolerance by increasing insulin secretion via the GLP-1 receptor and by reducing weight.

The leucine residues at position 14 and 26 and the phenylalanine residue at position 22 of this peptide are isotopically labelled with carbon-13 (6) and nitrogen-15 (1) giving this peptide a mass increase of 24 compared to the unlabelled peptide.

Oxyntomodulin Heavy

Cat No.Pack SizePriceQty.
25nmol£220.00
Bulk Quote